Partnering In China – Slow Gains In Store?

As more multinational drug makers divest/license their maturing or non-core assets to local Chinese firms, a fast pick-up in sales in China via these alliances does not always appear to be ensured, at least early on. Scrip delves into one such recent agreement between Lilly and 3SBio, one of China's most successful biotechs.